NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Status Not yet recruiting

Clinical Trial Summary

This research study involves studying a device as a possible treatment for metastatic melanoma in the brain. The purpose of this study is to obtain information on the safety and effectiveness of the study device, NovoTTF-200A, in melanoma participants with brain metastases when it is combined with Pembrolizumab. The name of the study device involved in this study is: -- NovoTTF-200A The name of the drug used in this study is: -- Pembrolizumab

Clinical Trial Description

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. - The name of the study device involved in this study is: NovoTTF-200A - The name of the drug used in this study is: Pembrolizumab - Eligible participants will be in this research study for up to 2 years, or until progressive disease or unacceptable toxicity as is reflected in the protocol. - This is a Phase I/II clinical trial. - A Phase I clinical trial tests the safety and toxicity of adding an investigational device NovoTTF-200A to standard-of-care drug Pembrolizumab to use for further studies. - A Phase II clinical trial tests how well the combination works for your brain disease. "Investigational" means that the device is being studied. The FDA (the U.S. Food and Drug Administration) has not approved NovoTTF-200A for your brain metastasis from melanoma. A metastatic brain tumor is usually found when a cancer patient begins to experience neurological symptoms and a brain scan (CT or MRI) is ordered. However, some participants are symptom-free and are only diagnosed with brain metastases with MRI or CT scans for another reason. The NovoTTF-200A System is a portable device which produces changing electrical fields, called Tumor Treatment Fields ("TTFields") within the human body. TTFields stop the growth of tumor cells resulting in cell death of the rapidly dividing cancer cells. TTFields may also sensitize the tumor cells to immune therapies and this is the rationale for combining NovoTTF-200A and Pembrolizumab. The system is a portable, light-weighted, battery operated device designed to deliver TTFields directly to the region where brain metastasis are. The device can be carried backpack while working or doing other activities of daily living. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04129515
Study type	Interventional
Source	Brown University
Contact	Eric T Wong, MD
Phone	401-444-0115
Email	ewong1@lifespan.org
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	April 15, 2024
Completion date	January 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02224781` - Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Phase 3
Active, not recruiting	`NCT05470283` - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma	Phase 1
Recruiting	`NCT05388877` - E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma	Phase 1
Active, not recruiting	`NCT05103891` - Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations	Phase 1
Completed	`NCT00414765` - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma	Phase 4
Completed	`NCT02857270` - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Phase 1
Completed	`NCT01621490` - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma	Phase 1
Recruiting	`NCT05779423` - Cryoablation+Ipilimumab+Nivolumab in Melanoma	Phase 2
Active, not recruiting	`NCT04940299` - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	Phase 2
Active, not recruiting	`NCT02278887` - Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma	Phase 3
Active, not recruiting	`NCT02360579` - Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma	Phase 2
Terminated	`NCT02521870` - A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1/Phase 2
Completed	`NCT02177110` - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Withdrawn	`NCT01340729` - Open-Label Study of TPI 287 for Patients With Metastatic Melanoma	Phase 1/Phase 2
Withdrawn	`NCT01416844` - Study of Immune Responses in Patients With Metastatic Melanoma	Phase 2
Terminated	`NCT01468818` - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00984464` - Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00631618` - Clinical Trial of Sutent to Treat Metastatic Melanoma	Phase 2
Terminated	`NCT00571116` - Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy	Phase 1
Recruiting	`NCT00226473` - Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma	Phase 4